Vor Biopharma stockholders elect Lubner and Resnick as Class II directors, ratify EY as auditor

Vor Biopharma Inc.

David C. Lubner elected with 53,754,258 votes for, 45,048 withheld (4,500,866 broker non-votes).
Joshua Resnick, M.D. elected with 44,270,251 votes for, 9,529,055 withheld (4,500,866 broker non-votes).
Ratification of Ernst & Young as independent auditor for FY2023 approved: 58,294,758 for, 1,908 against, 3,506 abstentions.
Approximately 87% of outstanding shares (58.3M) represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-26 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-26

Exact text from the filing

Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the following votes: Votes For Votes Against Abstentions 58,294,758 1,908 3,506

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vor Biopharma Inc. shareholders approved Election of Two Class II Directors David C. Lubner and Joshua Resnick, M.D. at the 2023-05-26 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-26

Exact text from the filing

by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes David C. Lubner 53,754,258 45,048 4,500,866 Joshua Resnick, M.D. 44,270,251 9,529,055 4,500,866

View on SEC.gov

641 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-155416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.